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ABSTRACT 
 
Chronic inflammation contributes to skeletal muscle atrophy and impaired regenerative 
capacity. Previous research has identified skeletal muscle inflammatory susceptibility (MuIS), or 
the ability to manage and respond to inflammation, as a predictor of failed skeletal muscle 
regeneration and regrowth following surgery. This inflammatory susceptibility is associated with 
human aging and likely contributes to the adverse structural, metabolic, and functional tissue 
remodeling that occurs in aged adults. The etiology for heightened inflammation in skeletal 
muscle is unclear, particularly in healthy young adults. Research that elucidates the mechanisms 
by which inflammation impairs skeletal muscle regeneration is necessary for identifying 
potential therapeutic targets. 
 Previous research from our laboratory identified kisspeptin-1 (KISS1) as a highly 
differentially expressed gene (DEgene) associated with lower inflammatory susceptibility 
(MuIS-) in human skeletal muscle. When the MuIS- group was compared to a group with an 
improved hypertrophic response to resistance training, gonadotropin-releasing hormone (GnRH) 
signaling emerged as a top canonical pathway. In the present study, we aimed to investigate the 
potential relationship between KISS1/GnRH signaling and inflammation in skeletal muscle and 
elucidate the relevant signaling pathways. 
The presence of the GnRH receptor (GnRHr) was assessed in the skeletal muscle of mice 
genetically modified to constitutively express β-galactosidase at the GnRHr promoter (RG) and 
wild type (WT) mice using a β-galactosidase gene detection assay. Cell culture experiments 
using differentiated human muscle progenitor cells (hMPCs) and immortalized mouse skeletal 
muscle stem cells (C2C12 cells) were performed to determine activation of canonical GnRH 
signaling (i.e., mitogen-activated protein kinases [MAPKs]), following treatment with Buserelin, 
a GnRH analog. The National Center for Biotechnology Information (NCBI) Gene Expression 
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Omnibus (GEO) datasets were searched for pathological conditions in which KISS1, KISS1 
receptor (KISS1r), GnRH, or GnRHr was differentially expressed in skeletal muscle and under 
inflammatory conditions in other organs. Results were analyzed using the NCBI software 
GEO2R, which contains R packages from the Bioconductor project. Lastly, the potential 
relationship between GnRH and inflammatory signaling was assessed using reverse 
transcription-polymerase chain reaction (RT-PCR) analysis of interleukin 6 (IL-6) following 
treatment with Buserelin and the inflammatory cytokine tumor necrosis factor alpha (TNFa). 
GnRHr was detected at the protein level in RG but not WT muscle, which validates the 
presence of GnRHr in skeletal muscle tissue. GnRH signaling may activate extracellular signal-
related kinase (ERK) in human skeletal muscle. Additionally, the transcription factor cAMP 
response element-binding protein (CREB) and Jun N-terminal kinase (JNK) have the capability 
to respond to Buserelin and Antide treatments in differentiated C2C12 cells. KISS1/GnRH 
expression was found to be downregulated in several inflammatory myopathies, including 
juvenile dermomyositis, Duchenne muscular dystrophy, amyotrophic lateral sclerosis, 
facioscapulohumeral dystrophy, tibial muscular dystrophy, and myotonic dystrophy type 2. 
GnRH did not impact the acute TNFa-mediated increase in IL-6 mRNA levels in skeletal 
muscle. 
Our data confirm that GnRHr protein is present and functional in skeletal muscle. 
Further, our results demonstrate that KISS1/GnRH have a relationship with inflammation that is 
impacted with inflammatory susceptibility and myopathies with signaling that may occur 
through the MAPK signaling pathway. Future research should focus on identifying phenotypes 
associated with a lack of KISS1 or GnRH signaling in skeletal muscle; KISS1/GnRH is a 
potential therapeutic target to attenuate heightened inflammation in disease states.  
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CHAPTER 1. INTRODUCTION 
1.1 Skeletal Muscle Structure and Function 
Skeletal muscle is the largest organ system in the human body, in individuals with a 
normal body mass index (BMI) (1). Muscle tissue is structurally comprised of multinucleated 
cells (myofibers), which are encapsulated by a cell membrane (the sarcolemma) and further 
arranged in bundles (fascicles). Fascicles, surrounded by a connective tissue layer (the 
perimysium), are bundled together to form entire muscles, which are covered by the epimysium 
layer. The myofiber of the muscle contains that contractile unit, the sarcomere, which is 
important for the physical functions of muscle. Skeletal muscle is a remarkably dynamic and 
resilient tissue with functions ranging from voluntary movement and nutrient homeostasis to 
temperature regulation and protection (2). Given the central functions of the muscle, 
maintenance of skeletal muscle structural and functional homeostasis is vital to overall human 
health and quality of life. 
 
1.2 Skeletal Myogenesis 
Throughout the life-course the skeletal muscle undergoes damage that requires tissue 
repair, regeneration, and even regrowth. Skeletal muscle damage may be caused by eccentric 
muscle contractions; surgery; and crush, burn, or blunt injuries, among others (3). When tissue 
damage occurs, a process known as regeneration takes place, allowing the tissue to regain 
functionality. The regenerative capacity of skeletal muscle relies on the resident adult stem cells, 
known as satellite cells (SCs), that surround myofibers in the space between the sarcolemma and 
basal lamina (4). In an essential step of the carefully orchestrated myogenic program, quiescent 
SCs are activated in response to injury-associated cues. Activation of the SCs can trigger 
symmetric or asymmetric proliferation, which yields a muscle progenitor cell (myoblast) and a 
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SC. Myoblasts further differentiate (myocytes) and fuse to form or repair the multinucleated 
myofibers (myotubes in culture). Less severe damage causes SCs to fuse with and strengthen 
existing myofibers, while more severe damage promotes the development of new myofibers (3, 
5). With asymmetric cell division, a portion of the activated SCs return to a quiescent state and 
maintain the reserve of stem cells. Given the role of SCs in the generation of myofibers, SCs, 
harvested from skeletal muscle tissue that are further cultured, are an optimal model to study not 
only myogenesis, but also factors that impact skeletal muscle health. 
 
1.3 Inflammation in Skeletal Muscle 
The acute inflammatory response following skeletal muscle injury, is essential for normal 
recovery and regeneration of the muscle (6). Inflammatory signals are required to activate SCs. 
In response to muscle damage, the proinflammatory cytokines tumor necrosis factor alpha 
(TNFa) and interleukin 1β (IL-1β) are released by the muscle itself or by resident macrophages 
(7,8). These proinflammatory cytokines activate the nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) pathway. NF-κB is a transcription factor that upregulates the 
expression of additional proinflammatory genes, notably TNFa, IL-1β, and interleukin 6 (IL-6) 
(Figure 1). These proinflammatory cytokines are important in recruiting neutrophils and 
additional macrophages that promote proteolysis and clear tissue debris following injury (9). 
Macrophages also secrete growth factors that are important for SC and myoblast proliferation. 
TNFa also activates SC proliferation, in addition to accelerating the transition from G1 to S 
phase of the cell cycle and participating in the regulation of myogenesis. (10, 11, 12). Within the 
last several decades, it has become apparent that precisely regulated crosstalk between the 
inflammatory response and muscle cells is necessary for successful myogenesis. 
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Figure 1. Inflammatory Cytokine Signaling. 
 
Despite the necessity of acute inflammatory signaling in the early stages of muscle 
regeneration and repair, chronically heightened inflammation contributes to skeletal muscle 
atrophy and impaired regenerative capacity (13). Previous research identified skeletal muscle 
inflammatory susceptibility, or the ability to manage and respond to inflammation, as a predictor 
of failed skeletal muscle regeneration and regrowth following surgery (14, 15). This 
inflammatory susceptibility is associated with human aging and likely contributes to the adverse 
structural, metabolic, and functional tissue remodeling that occurs in aged adults (14). 
Proinflammatory cytokines play central roles in muscle wasting and tissue remodeling. In the 
skeletal muscle of cachectic tumor-bearing mice, circulating levels of IL-6 were associated with 
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suppression of protein synthesis by inhibiting the activation of the mammalian target of 
rapamycin complex 1 (mTORC1), a complex that is important for protein synthesis and cell 
proliferation (16). Similarly, infusion of TNFa or IL-1β into skeletal muscle in vivo inhibited 
protein synthesis and promoted catabolism in rats (17). TNFa also prevented differentiation of 
myoblasts in vitro by repressing MyoD, an early marker of myogenic commitment (18, 19).  
Chronic inflammation-induced skeletal muscle deterioration is governed by similar 
proinflammatory signaling pathways that regulate the acute inflammatory response to injury. 
Upregulation of the NF-𝜅Β proinflammatory pathway has been implicated in animal models of 
cancer cachexia (20, 21, 22). Activation of NF-κB positively regulates the expression of murine 
ring finger-1 (MuRF1), an E3 ubiquitin ligase protein that is central in muscle atrophy and 
wasting (23). The p65 subunit of NF-κB, which potentiates canonical NF-κB signaling, has been 
associated with impaired myogenesis. In a mouse model with reduced p65 NF-κB activity, SC 
proliferation, myogenic differentiation, and regenerative capacity of skeletal muscle were 
enhanced in vitro and in vivo (24).  
Myopathies, diseases of the skeletal muscle, are often closely associated with 
dysregulated inflammatory signaling (25). Idiopathic inflammatory myopathies are characterized 
by persistent infiltration of innate immune cells, overactive protein degradation, and pathological 
tissue remodeling leading to fibrosis (26). In the context of aging, myopathy, or other conditions 
associated with a heightened inflammatory state, chronic inflammation in skeletal muscle is a 
hallmark of impaired myogenesis and muscle deterioration. While dysregulation of inflammatory 
signaling pathways are known to underlie muscle protein degradation, disruption of the 
myogenic program, and impediments in successful tissue regeneration, therapies to attenuate 
chronic inflammatory signaling in muscle are lacking.  
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1.4 KISS1/GnRH—Novel Mechanism Associated with Skeletal Muscle Inflammation 
In previous research from our laboratory (27), cultured and differentiated human primary 
SCs, from young male and female donors, were separated into two clusters based on the 
expression of pro-inflammatory cytokines IL-6, IL-1β, and TNFα expression; the two clusters 
were myocytes with (MuIS+) and without (MuIS-) inflammatory susceptibility. RNA-
sequencing (RNA-seq), on a subset of MuIS+ (n = 4) and MuIS- (n = 4), was used to confirm the 
donor myocyte culture classification with principal components analysis (PCA) (Figure 2A) and 
to determine the mechanisms underlying inflammation susceptibility in the MuIS+. We 
identified 573 differentially expressed (DEgenes) (178 downregulated and 395 upregulated) 
between MuIS+ and MuIS-. The RNA-seq data was validated using quantitative, real-time 
polymerase chain reaction (RT-PCR) for five genes that were differentially expressed between 
MuIS+ and MuIS- clusters (Figure 2B). Genes used for validation included pro-inflammatory, 
degradative, and myogenic genes. Further, Ingenuity Pathways Analysis (IPA) was performed 
for pathway enrichment to identify potential mechanisms underlying inflammatory susceptibility. 
 
A 
  6 
 
Figure 2. MuIS+ and MuIS- Clusters. (A) Principal component analysis of the log2FPKM 
values was used to reduce the dimensionality and unbiasedly cluster the RNA-seq data. (B) 
Validation plot comparing the fold-change between RT-PCR and RNA-seq for five genes that 
were differentially expressed between MuIS+ and MuIS- clusters.  
 
Unexpectedly, we identified that kisspeptin-1 (KISS1) had the greatest difference in gene 
expression between MuIS+ and MuIS- (downregulated 21.4-fold [MuI+/MuIS-]) Further, KISS1 
was identified as a node in the top network (Network 1) of DEgenes following pathway analysis. 
Network 1 had over-representation of DEgenes related to Organ Morphology, Reproductive 
System Development and Function, and Tissue Morphology (Figure 3).  
 
B 
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Figure 3. Network of DEgenes. KISS1 was identified as a node in a top network of DEgenes 
following IPA. Nodes represent a gene or gene product and edges represent signals, such as 
activation or repression, that go from one node to another. Red, upregulated; Green, 
downregulated. 
 
 
Further, we compared the canonical pathways identified using the DEgenes for 
MuIS+/MuIS- with the canonical pathways of DEgenes from non- versus extreme hypertrophic 
responders. Non- and extreme-hypertrophic responder classification was determined via 
myofiber growth following 16 weeks of progressive resistance training (28). Non-responders had 
over-representation DEgenes in pro-inflammatory functional categories (29). Intriguingly, 
gonadotropin-releasing hormone (GnRH) signaling was identified as a top canonical pathway, 
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down-regulated, in MuIS+ myocytes and non-responder skeletal muscle tissue. KISS1 has 
regulatory roles through GnRH, but the relationship among KISS1, GnRH, and inflammation in 
the skeletal muscle is unknown.  
 
1.5 Canonical Roles of KISS1 and GnRH 
Kisspeptins are a family of proteins encoded by the KISS1 gene in humans. Kisspeptins 
are cleaved from a 145 amino acid precursor peptide and include the fragments kisspeptin-54, 
kisspeptin-10, kisspeptin-13, and kisspeptin-14. All kisspeptins bind to the kisspeptin receptor 
(KISS1r), also known as G protein-coupled receptor 54 (GPR54), with equal affinity (30). 
KISS1r is coupled to the Gαq/11 signaling pathway, where activation of the primary effector 
phospholipase C (PLC) results in the production of inositol-(1,4,5)-trisphosphate (IP3) and 
diacylglycerol, mobilization of calcium, and activation of protein kinase C (PKC) and 
extracellular signal-regulated kinases 1 and 2 (ERK1/2). KISS1/KISS1r signals through these 
secondary messengers in multiple cell types (31).  
The mitogen-activated protein kinase (MAPK) signaling pathways regulate cellular 
processes including cell proliferation, differentiation, and survival or apoptosis (Figure 4) (32, 
33). MAPK pathways, including ERK1/2, p38 MAPK, and c-Jun N-terminal kinase (JNK), are 
key regulators of the inflammatory response in various human diseases (34). ERK, a known 
regulator of cell proliferation, is regulated by KISS1 in many tissues (31). ERK is involved in the 
response to DNA damage and is dysregulated in many human cancers, leading to tumorigenesis 
and resistance to anticancer therapies (35). KISS1 binding to its receptor can activate ERK1/2 
through both the Gαq/11 and β-arrestin-2 pathways (36). 
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Figure 4. The MAPK Pathways. The ERK and JNK pathways are key regulators of the 
inflammatory response and are regulated by KISS1 and/or GnRH in many tissues. Taken from 
Morrison, 2012 
 
KISS1 is widely known for its regulatory role in the hypothalamic-pituitary-gonadal axis, 
which occurs through the activation of GnRH neurons. KISS1 and KISS1r are expressed by 
neurons in the arcuate nucleus and anteroventral periventricular nucleus (AVPV) of the 
hypothalamus (38, 30). In response to KISS1, the hypothalamic decapeptide hormone GnRH is 
released by GnRH neurons into the hypophyseal portal capillary system and acts on 
gonadotropes of the anterior pituitary gland to stimulate the production of luteinizing hormone 
(LH) and follicle-stimulating hormone (FSH). LH and FSH travel through systemic circulation to 
promote the synthesis and release reproductive hormones from the gonads, leading to ovarian 
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follicular development and testicular spermatogenesis (39). KISS1/KISS1r signaling is required 
for the onset of puberty and normal reproductive function in mammals (30, 37, 39). 
KISS1 has also been proposed as a major regulator of placentation and fetal development 
based on its roles in inhibition of trophoblast migration and invasion (40). Because of its ability 
to induce oocyte maturation, KISS1 has been effectively used as fertility treatment in women 
undergoing in vitro fertilization (IVF), conferring a lower risk of ovarian hyperstimulation 
syndrome (OHSS) than human chorionic gonadotropin (hCG) treatment (41). This method of 
IVF is particularly relevant for treating infertility in women with polycystic ovarian syndrome 
(PCOS), who are at a five-fold higher risk of developing OHSS (41). 
 
1.6 KISS1 and GnRH Signaling 
The ERK signaling cascade is also responsible for the major biological effects of GnRH. 
LH transcription is dependent on ERK-induced expression of EGR1, and ERK1/2 ablation in the 
pituitary of female mice results in anovulation (42). In an immortalized human cervical cancer 
cell line (HeLa cells) transduced to express the GnRH receptor (GnRHr), treatment with GnRH 
induced a maximum response of ERK1/2 activation at 5 min followed by a rapid decrease to 
nearly basal levels by 60 min (43). In the pituitary gonadotrope, GnRH activates ERK1/2 in a 
calcium-dependent manner, facilitating voltage-gated L-type channels to open and allow calcium 
influx (44). In systems such as the pituitary, GnRHr couples to the Gs alpha subunit (G⍺s) and 
stimulates cAMP (45). GnRHr-induced calcium-dependent cAMP elevation has been proposed 
as a Gαs-independent mechanism of GnRH signaling (44, 46, 47). GnRH also signals transiently 
through JNK MAPK in rat pituitary gonadotropes. While GnRH-induced activation of ERK 
requires extracellular calcium, GnRH signaling through JNK relies on intracellular calcium (48). 
In addition to ERK and JNK, GnRH signals through cAMP response element-binding protein 
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(CREB), a member of the leucine zipper superfamily of transcription factors. CREB is involved 
in the stress response and regulates cell survival and proliferation in most human tissues (49). 
GnRH signaling is precisely controlled by several factors upstream of KISS1. Estrogen, a 
primary sex hormone, exerts both negative and positive feedback on GnRH secretion by acting 
on kisspeptin/neurokinin B/dynorphin (KNDy) neurons in the arcuate nucleus and kisspeptin-
releasing AVPV nucleus, respectively (37, 49). The positive feedback response to estrogen in 
AVPV neurons causes an LH surge only in females, and this sexual dimorphism allows for sex-
specific hormonal responses (49). In addition to its role in the reproductive system, estrogen 
stimulates skeletal muscle repair and regeneration via SC activation and proliferation and has 
been associated with a suppressed inflammatory response in skeletal muscle in response to injury 
(50, 51, 52, 53). 
 
1.7 KISS1/GnRH in Cellular Processes 
KISS1 is potent suppressor of metastasis and has been shown to inhibit the TNFα-
mediated activation of NF-κB signaling in breast cancer cells (54). Metastasis suppressors, 
defined by their ability to inhibit metastasis without blocking orthotopic tumor growth, are 
central therapeutic targets in human cancers (55). Following transfection with KISS1 and its 
constitutive expression, metastasis was suppressed in human malignant melanoma cells and in a 
highly metastatic sub-clone (56). KISS1 is downregulated during human melanoma progression 
in vivo, likely due to a loss of heterozygosity and inactivation of a tumor suppressor gene 
localized on the same chromosome (57, 58). KISS1 suppresses the migration of pancreatic 
cancer cells and simultaneously activates ERK1/2 (59, 60). In gastric cancer, reduced KISS1 
gene expression is associated with distant metastases, worsened survival, and lymph node and 
liver metastases tumors (61, 62, 55). Since their discovery, kisspeptins have been explored as 
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therapeutic targets for melanoma, thyroid cancer, bladder cancer, esophageal carcinoma, gastric 
cancer, hepatocellular carcinoma, and breast cancer (30). Originally, cytoskeleton remodeling 
was proposed as a mechanism of KISS1/KISS1r action in breast cancer cells, as KISS1-
transfectants spread on type-IV collagen more quickly than control cells (56). As KISS1 acts 
through MAPK pathways, regulation of cell proliferation and motility have also been implicated 
in the anti-metastatic capabilities of KISS1 (30). 
 
1.8 KISS1/GnRH Signaling and Inflammation 
KISS1 negatively regulates inflammatory signaling. In cervical and ovarian cancer cell 
lines, KISS1/KISS1r binding inhibited chemokine signaling (63). KISS1 has been shown to 
inhibit the TNFα-mediated activation of the NF-κB pathway in breast cancer cells and 
dephosphorylate NF-κB in fibrosarcoma cells, resulting in dissociation from the matrix 
metalloprotease 9 MMP-9 (MMP-9) promoter via a MAPK-independent mechanism (54, 64). 
Further, a knockdown of a metastasis-promoting gene in breast cancer cells led to the 
upregulation of KISS1, inhibition of MMP-9, lower levels of NF-κB p65/50 subunits in the 
nucleus, and blunted metastatic response to treatment with TNFa (65). 
While KISS1 has been shown to negatively regulate inflammatory pathways, several 
studies have also identified that KISS1/KISS1r signaling is dysregulated with inflammation. An 
acute inflammatory challenge with lipopolysaccharide (LPS) has been shown to decrease KISS1 
mRNA expression in the hypothalamus (66) and microarray analysis of rat trigeminal ganglion 
tissue after treatment with complete Freund's adjuvant, which stimulates an acute inflammatory 
response, demonstrated a 1.7-fold downregulation in KISS1 and 9.2-fold downregulation in 
KISS1r (67). Given the evidence for contrasting roles of KISS1 in relation to inflammation, the 
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directionality of the hypothesized relationship between KISS1 and inflammation in skeletal 
muscle is unclear. 
Inflammation has also been shown to dysregulate GnRH signaling in the hypothalamus, 
pituitary, and peripheral tissues. Leukemia inhibitory factor (LIF), a neuroinflammation-induced 
cytokine, has been shown to reduce spine density, a measure of excitatory synaptic input, of 
GnRH neurons in the hypothalamus. This inflammation-induced decrease in GnRH neuron spine 
density was specific to male mice, while protection in females was independent of ovarian 
estrogens (68). Administration of LPS suppressed gonadotropic function in male rats, likely due 
to a reduction in absolute responsiveness of GnRH neurons to KISS1 (69). These data suggest 
that similar to KISS1 signaling, GnRH has a relationship with inflammation in several tissues.  
 The genetic absence of KISS1 is associated with several phenotypes. In humans, 
mutations in the KISS1 gene in lead to congenital idiopathic hypogonadotropic hypogonadism, a 
disorder characterized by incomplete or absent sexual maturation by the age of 18 years 
accompanied by low levels of circulating testosterone and gonadotropins (70). Whole-body 
KISS1r genetic knockout mice exhibit reduced lean body mass and higher liver kinase β1 
(LKβ1) gene expression in skeletal muscle, with a more robust decrease in males (71). LKβ1 
suppresses growth and proliferation through activation of AMP-activated protein kinase (AMPK) 
and inhibition of mTORC1 (72). However, because the suppression of sex hormones has a 
significant effect on skeletal muscle development and regenerative capacity (51, 53), the whole-
body KISS1r knockout is not sufficient for isolating the roles of endogenous KISS1/GnRH 
signaling in skeletal muscle. A muscle-specific KISS1 genetic knockout model would be 
necessary to identify the phenotypes associated with a lack of KISS. 
 
1.9 Conclusions  
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Chronic inflammation underlies skeletal muscle atrophy and impaired regenerative 
capacity (6, 13), however, therapies to attenuate inflammation during aging and disease are 
lacking. In previous research from our laboratory, we found that KISS1 and GnRH were 
associated with a lower inflammatory susceptibility in skeletal muscle (27). In addition to its 
roles in maintaining reproductive function and suppressing tumor metastasis, KISS1 signaling 
has been associated with suppressing inflammation in other tissues (54, 73). KISS1 and GnRH 
both signal through MAPK pathways, pathways that bridge inflammation and myogenic 
processes (41). Research that investigates the potential relationship between KISS1 and/or GnRH 
signaling and inflammation in skeletal muscle offers a novel therapeutic target for chronic 
inflammation and thus, requires further exploration. 
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CHAPTER 2. KISSPEPTIN AND GONADOTROPIN-RELEASING HORMONE SIGNALING 
IN SKELETAL MUSCLE 
 
2.1 Abstract 
Chronic skeletal muscle inflammation contributes to skeletal muscle atrophy and 
impaired regenerative capacity. Previous research from our laboratory identified that kisspeptin-
1 (KISS1) and the gonadotropin-releasing hormone (GnRH) signaling pathway were associated 
with lower inflammatory susceptibility (i.e., the ability to manage and respond to inflammation) 
and an improved hypertrophic response in the skeletal muscle. Objective: The objectives of this 
research were to verify the presence of the GnRHr protein in skeletal muscle, elucidate 
mechanisms of KISS1/GnRH signaling in muscle cells, and investigate the potential relationship 
between KISS1/GnRH signaling and inflammation in skeletal muscle. Methods: To confirm the 
presence of GnRHr in the skeletal muscle, we extracted the skeletal muscle of ROSA26/GnRHr 
internal ribosomal entry site Cre (ROSA GRIC [RG]) and wild type (WT) mice and measured β-
galactosidase using a commercially available kit. To evaluate downstream GnRH/GnRHr 
signaling, we used differentiated human primary muscle stem cells (myocytes) and immortalized 
myoblasts (C2C12 cells) treated with Buserelin, a GnRH analog, and Antide, a GnRH 
antagonist, and measured canonical GnRHr signaling (i.e. MAPK signaling pathways) with 
immunoblotting. To evaluate the potential relationship between inflammation and 
GnRH/GnRHr, NCBI Gene Expression Omnibus (GEO) datasets were searched and analyzed for 
differential expression of KISS1/GnRH in skeletal muscle. Further, differentiated C2C12 cells 
were treated with Buserelin and tumor necrosis factor alpha (TNFa), a pro-inflammatory 
cytokine, and inflammatory signaling was assessed at the mRNA level using RT-PCR analysis. 
Results: We confirmed GnRHr in skeletal muscle; β-galactosidase was detected in RG but not in 
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WT muscle. In myocytes, extracellular signal-regulated kinase (ERK) signaling responded to 
Buserelin treatments. The transcription factor cAMP response element-binding protein (CREB) 
and Jun N-terminal kinase (JNK) responded to Buserelin and Antide treatments. Lastly, 
KISS1/GnRH expression is downregulated in several inflammatory myopathies; however, 
Buserelin did not impact TNFa-mediated IL-6 expression in myocytes. Conclusion: GnRHr 
signaling occurs in skeletal muscle, likely through MAPK signaling (i.e., ERK, CREB, JNK), 
and may be associated with inflammation. Future research is warranted to delineate the 
relationship between KISS1/GnRH/GnRHr and inflammation. 
 
2.2 Introduction 
Chronic inflammation, commonly observed with aging and disease, contributes to 
skeletal muscle atrophy and impaired regenerative capacity (1, 2). Previous research 
demonstrated that skeletal muscle inflammatory susceptibility (MuIS), or an impaired ability to 
regulate and respond to inflammation, is a predictor of failed skeletal muscle regeneration and 
regrowth following surgery (3, 4). Intriguingly, MuIS, measured in the skeletal muscle, is 
observed in healthy young males (4) and is also associated with human aging, likely contributing 
to the adverse structural, metabolic, and functional tissue remodeling that occurs in aged adults 
(3). 
The etiology for MuIS and chronic inflammation in skeletal muscle is unclear, 
particularly in healthy young adults. Kisspeptin (KISS1) and gonadotropin releasing hormone 
(GnRH) signaling were identified, in previous research from our lab, as potential therapeutic 
targets that are associated with MuIS (5). KISS1 was the most highly differentially expressed 
gene (DEgene) between a group of donor myocytes with (MuIS+) and without (MuIS-) 
heightened inflammation (downregulated 21.4-fold [MuIS+/MuIS-]) and was a node in the top 
  23 
network of DEgenes following pathway analysis in Ingenuity Pathways Analysis (IPA). Further, 
using IPA, the GnRH signaling pathway was identified as a top canonical pathway based on the 
overrepresentation of DEgenes between MuIS+ and MuIS- cells.  
KISS1 is best known for its role in the hypothalamic-pituitary-gonadal axis and activating 
GnRH neurons (6, 7). Pulsatile GnRH signaling is required for normal reproductive function and 
stimulates the release of anterior pituitary hormones into the systemic circulation. KISS1 and 
GnRH are commonly known to signal through the mitogen-activated protein kinase (MAPK) 
pathways: extracellular-regulated kinase (ERK), Jun N-terminal kinase (JNK), and the 
downstream transcription factor cAMP response element-binding protein (CREB). These 
pathways are known to link inflammation and myogenic processes. (8, 9, 10). 
Since its discovery, KISS1 has been investigated as a therapeutic target in a number of 
human cancers (6). KISS1 is downregulated during melanoma progression in vivo (11) and 
KISS1 transfection and constitutive expression suppresses metastasis in human malignant 
melanoma cells (12). KISS1 is also a potent tumor metastasis suppressor (13). Intriguingly, 
KISS1 has been shown to inhibit TNFα-mediated activation of the nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-κB) pathway in breast cancer cells (14) and 
dephosphorylate NF-κB in fibrosarcoma cells, resulting in dissociation from the matrix 
metalloprotease 9 (MMP-9) promoter (15).  
While KISS1 has been shown to regulate major proinflammatory pathways in cancer 
cells, several studies have identified that KISS1/KISS1r signaling itself is dysregulated under 
inflammatory conditions. An inflammatory challenge with lipopolysaccharide (LPS) decreases 
KISS1 mRNA expression in the hypothalamus (16) and treatment with an inflammatory stimulus 
leads to a 1.7-fold downregulation in KISS1 and 9.2-fold downregulation in KISS1r in rat 
trigeminal ganglion tissue (17). Inflammation also dysregulates GnRH signaling in the 
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hypothalamus, pituitary, and peripheral tissues. Leukemia inhibitory factor (LIF), a 
neuroinflammation-induced cytokine, has been shown to reduce spine density, a measure of 
excitatory synaptic input, of GnRH neurons in the hypothalamus of male mice (18). Finally, 
administration of LPS suppresses gonadotropic function in male rats, likely due to a reduction in 
absolute responsiveness of GnRH neurons to KISS1 (19). 
The observed relationship between KISS1/GnRH and inflammation in non-muscle cells 
underscores our findings and thus, supports our desire for further exploration of previous 
research from our lab. However, KISS1/GnRH protein has never been verified in the skeletal 
muscle. Further, it is important to establish whether KISS1/GnRH is also expressed in skeletal 
myopathies. Thus, the purpose of this research was to verify the presence of the GnRHr protein 
in skeletal muscle, elucidate mechanisms of GnRH signaling in muscle cells, and investigate the 
potential relationship between KISS1/GnRH signaling and inflammation in skeletal muscle. We 
hypothesize that GnRHr protein is present in skeletal muscle, GnRH signals through a MAPK 
pathway in skeletal muscle, and KISS1/GnRH signaling has a relationship with inflammation in 
skeletal muscle. 
 
2.3 Methods 
 
Ethical approval 
 
This study was approved by the Cornell University Institutional Review Board. Written 
informed consent was obtained from all human participants. All research involving animals was 
carried out in accordance with Cornell University’s Institutional Animal Care and Use 
Committee policies. 
 
Mouse skeletal muscle procurement and gene detection assay 
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To investigate whether GnRHr exists in skeletal muscle, we used a ROSA26/GnRHr 
internal ribosomal entry site Cre (ROSA26/GRIC) mouse model, which is a β-galactosidase 
knock-in model, designed to express β-galactosidase in tissues where GnRHr is expressed. 
Animals were sacrificed at 8 weeks of age using CO2 inhalation. Skeletal muscle tissue was 
obtained from the hindlimb of female and male ROSA26/GRIC (n = 5) and C57BL/6J mice (n = 
4) at 8 weeks of age. Tissue samples weighing ~30 mg were snap-frozen and stored at -80°C. 
Samples were pulverized and homogenized using the VWR PowerMAX 200 homogenizer 
(VWR). Protein was extracted using Radioimmunoprecipitation assay (RIPA) buffer 
supplemented with phosphatase and protease inhibitors (PhosSTOP tablets and cOmplete 
Protease Inhibitor Cocktail tablets, Sigma-Aldrich) and purified by centrifugation at 12,500 x g 
for 15 min, after which the supernatant was collected, and remaining pellet discarded. Protein 
levels were quantified using a bicinchoninic assay (BCA Protein Assay Kit, Pierce) with 
spectrophotometer (Epoch Microplate Spectrophotometer, BioTek). GnRHr was investigated at 
the protein level using the Galacto-Light Plus™ beta-Galactosidase Reporter Gene Assay System 
(Thermo Fischer) and analyzed with a SpectraMax M3 luminometer (Molecular Devices). The 
presence of β-galactosidase was detected by providing a chemiluminescent substrate and 
measuring luminescence as a representation of β-galactosidase activity. A standard curve was 
created using exogenous β-galactosidase (Promega) following the Promega protocol. 
 
Human subjects and tissue procurement  
 
Skeletal muscle tissue contains specialized adult stem cells (satellite cells) that reside 
between the sarcolemma and basal lamina. Satellite cells can be harvested from human muscle 
tissue and cultured. Cultured satellite cells, from human donors (muscle progenitor cells 
[hMPCs]), can be induced to differentiate (myocytes) and form multinucleated myotubes. 
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Because hMPCs and the myocytes retain properties of the in vivo state, they are an optimal 
model to study not only myogenesis, but also factors that impact skeletal muscle health.  
hMPCs from healthy, ambulant young male (n = 5) and female (n = 5) donors were used 
to address research objectives. Potential participants were recruited from the Tompkins County, 
New York area via flier and web-based announcements. All individuals completed a 
comprehensive health history and physical activity questionnaire and were independently 
ambulatory and cognitively intact as determined by the examining nurse practitioner. Individuals 
were excluded for contagious infections and any chronic end-stage disease expected to limit life-
expectancy to less than one year, induce anorexia, or restrict physical activity. Individuals with 
seated resting systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg and 
individuals receiving anabolic (e.g., growth hormone, insulin-like growth factor 1 [IGF-1]) 
therapy were also excluded.  
Skeletal muscle biopsies were performed by a nurse practitioner in the Human Metabolic 
Research Unit (HMRU) at Cornell University. After an overnight fast, subjects reported to the 
HMRU, vitals (i.e., heart rate and blood pressure) were measured, and subjects rested in the 
supine position. A percutaneous needle biopsy of the vastus lateralis was taken using a 5.0 mm 
Bergstrom biopsy needle with suction under local anesthetic (1% lidocaine). Tissue was quickly 
blotted with sterile gauze and visible adipose and connective tissues were removed. 
Approximately 75-100 mg of the total muscle biopsy was stored in Gibco® Hibernate®A 
(Thermo Fisher Scientific) at 4°C until tissue disassociation was performed. 
 
Purified, human primary muscle progenitor cells 
 
Biopsy tissue in Gibco® Hibernate®A (Thermo Fisher Scientific) was minced and 
washed via gravity with Ca-Mg free D-PBS. Minced and washed tissue was then disassociated in 
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digest medium (2 mg/mL Collagenase D [Roche] in low-glucose DMEM). After 30 min in digest 
medium, fresh digest medium and Dispase (Sigma) were added. The disassociating pellet was 
titurated until a uniform slurry was achieved. Growth medium ([GM] Hams F12 + 20% FBS + 5 
ng/mL bFGF [Promega] + 1% Pen/Strep [Gibco]) was added to the slurry and passed through a 
70 μm cell strainer into a sterile tube. The cell suspension was centrifuged. The pellet was 
resuspended in Recovery® freezing medium (Gibco) and cryopreserved at -80 °C. Thawed cells 
were seeded on a type-I collagen coated culture dish (initial cell confluency ~15%). Cells were 
cultured at 37 °C under 5% CO2 atmospheric conditions. After 24 h, the GM was replaced with 
fresh GM and further replenished every 48 h. Once cells reached ~70% confluency, they were 
removed from the plate using 0.25% Trypsin-EDTA and passaged. Cells were expanded to 
passage four, then cryopreserved in 10% DMSO + GM.  
Approximately 1-1.5 million cells were labeled with fluorescently-conjugated antibodies 
specific for myoblast cell surface antigens CD56 (NCAM; PE-Cy7-conjugated) and CD29 (β1-
integrin; AlexaFluor488-conjugated) and the viability stain 7-Aminoactinomycin D (7AAD) 
(187). Individual samples yield 150,000 – 800,000 viable CD56+/CD29+ hMPCs per 1 million 
cells sorted using a BD FACS Aria™ Fusion flow cytometer. Sorted CD56+/CD29+ cells were 
expanded in culture by passaging twice and then used in experiments; all in vitro experiments 
were performed using sorted cells at passage six.  
 
GnRH/GnRHr functional signaling pathway in human primary myocytes 
 
Sorted hMPCs were seeded at a density of approximately 10%. Throughout proliferation, 
GM was changed every 48 h. At ~70% confluence, hMPCs were switched to differentiation 
media ([DM] Ham’s F12 [Gibco] supplemented with 2% heat inactivated equine serum]. At 5 d 
post-differentiation, myocytes were serum-starved for 4 h during which time they were treated 
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with DM + 10 nM Buserelin (Buserelin acetate salt, Sigma-Aldrich). Buserelin is a GnRH 
agonist. This concentration of Buserelin has been used in culture settings in previous research. 
Cell lysate was collected at time 0 min, 5 min, 15 min, 30 min, 60 min, and 120 min after DM 
treatments with RIPA buffer supplemented with phosphatase and protease inhibitors (PhosSTOP 
tablets and cOmplete Protease Inhibitor Cocktail tablets, Sigma-Aldrich) and protein was 
purified by centrifugation at 12,500 x g for 15 min, after which the supernatant was collected, 
and remaining pellet discarded. Protein levels were quantified using a bicinchoninic assay (BCA 
Protein Assay Kit, Pierce) with a spectrophotometer (Epoch Microplate Spectrophotometer, 
BioTek). 
 
GnRH/GnRHr functional signaling pathway in C2C12 myocytes 
 
C2C12 cells (ATCC) were rapidly thawed from storage at -80°C and seeded onto 10 cm 
plates in C2C12 growth media ([CGM] Dulbecco’s Modified Eagle Medium supplemented with 
10% fetal bovine serum) to reduce variability introduced by the freeze-thaw process. CGM was 
changed at 24 h. At approximately ~70% confluency, cells were removed from the plate using 
0.25% Trypsin-EDTA, passaged, and seeded at a density of approximately 10% in CGM. At 
~70% confluence, cells were switched to C2C12 differentiation media ([CDM] Dulbecco’s 
Modified Eagle Medium supplemented with 2% heat inactivated equine serum). At 5 d post-
differentiation, C2C12 myocytes were serum-starved for 4 h during which time they were treated 
with CDM; CDM + 10 nM Buserelin (Buserelin acetate salt, Sigma-Aldrich); or CDM +100 nM 
Antide (Sigma-Aldrich) + 10 nM Buserelin (Antide was administered 30 min prior to Buserelin). 
Antide is a GnRH antagonist. This concentration of Antide has been used in culture settings in 
previous research. Cell lysate was collected at time 0 min, 5 min, 15 min, 30 min, 60 min, and 
120 min after CDM treatments with RIPA buffer supplemented with phosphatase and protease 
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inhibitors (PhosSTOP tablets and cOmplete Protease Inhibitor Cocktail tablets, Sigma-Aldrich). 
Protein was purified by centrifugation at 12,500 x g for 15 min, after which the supernatant was 
collected, and remaining pellet discarded. Protein levels were quantified using a bicinchoninic 
assay (BCA Protein Assay Kit, Pierce) with a spectrophotometer (Epoch Microplate 
Spectrophotometer, BioTek). 
 
Western blot analysis 
 Western blot analysis was used to determine protein levels on known GnRH/GnRHr 
functional signaling pathways, in human myocytes and differentiated C2C12 myocytes. Purified 
total protein extracts were diluted with double distilled water (ddH2O) and Laemmli loading 
buffer to standardize protein content to 12 ug, loaded in 10% SDS gels, and transferred to 
biological membranes overnight at 4 °C. Membranes were blocked for 1 h in a chemiluminescent 
blocking agent (Immobilon Block, Millipore). Primary antibodies (Cell Signaling Technology) 
against p-ERK1/2 (1:1,000), total ERK1/2 (1:1000), p-JNK (1:1000), JNK (1:1000), p-CREB 
(1:1000), total CREB (1:1000), and α-tubulin (1:1000) were diluted in blocking agent 
(Immobilon Block, Millipore). Membranes were incubated in primary antibody solutions 
overnight at 4° C on a rocker. Membranes were washed in tris-buffered saline supplemented with 
Tween 20 (TBST) three times on a rocker, for 5 min each, before incubation in secondary 
antibody. Horseradish peroxidase-conjugated secondary rabbit antibodies were diluted 1:100,000 
and mouse antibodies 1:125,000 in blocking agent. Membranes were incubated in secondary 
antibody for 1 h at room temperature on a rocker and washed again as indicated above. Blots 
were developed in imaging solution (SuperSignal West Femto Stable Peroxide Buffer and 
Luminol/Enhancer Solution, Thermo Scientific) and analyzed with the ChemiDoc MP Imaging 
System (Bio Rad). Prior to reuse, membranes were stripped for 5 min with Restore PLUS 
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Western Blot Stripping Buffer (Thermo Scientific) and checked for remaining bound antibody 
using the ChemiDoc before subsequent blocking. All blots were normalized to the housekeeper 
α-tubulin. 
 
KISS/GnRH gene expression in GEO Datasets 
The National Center for Biotechnology Information (NCBI) Gene Expression Omnibus 
(GEO) Datasets were searched for conditions in which KISS1, KISS1r, GnRH, or GnRHr was 
differentially expressed in skeletal muscle tissue (Figure 1). Search terms included "muscle, 
skeletal "[MeSH Terms] OR skeletal muscle [All Fields]. GEO2R software was used to run 
statistical analyses. Two or more groups were compared to identify differentially expressed 
genes (DEgenes) across conditions or treatment groups. Comparisons were performed using 
GEOquery and Linear Models for Microarray Analysis (limma), which are R packages from the 
Bioconductor project (20). Bioconductor is an open source software project that aids in analyses 
of high-throughput genomic data. GEOquery parses data into R structures that are usable to other 
R packages. Limma is the most widely used statistical test to identify DEgenes. Results were 
collected from a table of DEgenes arranged in order of statistical significance. All p-values 
presented were adjusted for false discovery rate using the Benjamini & Hochberg procedure, the 
most common multiple-testing correction for microarray data. The Benjamini & Hochberg 
adjustment provides a balance between detecting statistically significant differences and avoiding 
false positives. Graphs were generated using the “Profile Graph” feature and Microsoft Excel. 
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Figure 1. Literature Search of NCBI GEO Datasets. 
 
GnRH signaling and inflammatory cytokine gene expression 
 Sorted hMPCs from young female (n = 5) and young male (n = 5) donors were seeded at 
a density of approximately 10%. Throughout proliferation, GM was changed every 48 h. At 
~70% confluence, hMPCs were switched to DM and differentiated for 5 days (myocytes). 
Myocytes were treated for 48 h with DM (control); DM + 10 ng/mL TNFα; DM + 10 nM 
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Buserelin; or DM + 10 ng/mL TNFα + 10 nM Buserelin. 15 min prior to harvest, fresh 
treatments were administered to myocytes. RNA was harvested using TRK lysis buffer (Omega) 
following manufacturer’s instructions. Total RNA was purified using an EZNA total RNA kit 
(Omega) following manufacturer’s instructions. cDNA was synthesized using the High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems). Real-time, quantitative PCR (RT-PCR) 
was performed using the LightCycler 480 system (Roche) with the TaqMan Fast Advanced 
Master Mix and TaqMan® Gene Expression Assays (Applied Biosystems) to identify 
differences in gene expression of IL-6. 18S (Hs99999901_s1) was used as the housekeeper. 
 
Statistical Analyses 
 
Protein levels of GnRHr signaling and mRNA levels of inflammatory cytokines, in 
myocytes, were analyzed using a two-way analysis of variance (ANOVA) with Tukey post hoc 
tests if the interaction term was significant. All statistical tests on mRNA data were performed 
using the delta Cp (dCP) values for IL-6 and 18s. All statistical analyses of experimental results 
were completed using GraphPad Prism4. All values are reported as mean ± s.d.. Significance was 
set at p < 0.05. 
 
2.4 Results 
GnRHr gene detection in skeletal muscle 
The ROSA26/GRIC mouse model is a β-galactosidase knock-in, designed to express β-
galactosidase in tissues where GnRHr is expressed. β-galactosidase enzyme activity was detected 
in the skeletal muscle of the ROSA26/GRIC mice but not in the C57BL/6J (WT) mice (Figure 
2). This result validates the presence of GnRHr in skeletal muscle and confirms our hypothesis 
that GnRHr protein exists in skeletal muscle. While we could not determine statistical 
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differences between males and females for GnRHr, the ROSA26/GRIC males appeared to have 
greater β-galactosidase activity compared to the ROSA26/GRIC females (Figure 2). 
 
 
Figure 2. GnRHr Validation. β-galactosidase enzyme activity was measured using 
luminescence and normalized to total protein in skeletal muscle harvested from female (F) and 
male (M) ROSA26/GRIC (RG) and C57BL/6J (WT) mice. Data are presented as individual 
mice. 
 
 
GnRH/GnRHr functional signaling pathway in skeletal muscle 
To further validate the presence and function of GnRH/GnRHr in skeletal muscle, we 
measured canonical signaling, through MAPK signaling pathways, in human primary myocytes 
treated with Buserelin, a GnRH analog. Buserelin treatment caused a transient, upward spike in 
activation of the ERK1 signaling pathway over time, with a decline in p-ERK at 2 h (p= 0.19, 
Figure 3). However, there was large variation in activity among cultures, which is common with 
human primary cells; thus, we did not observe a statistically significant difference in Buserelin-
induced activation of ERK. Therefore, we repeated the time course experiment using C2C12 
myocytes. In C2C12 myocytes, there was no effect of Buserelin alone, over time, on p-ERK 
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(Figure 4A-B), p-CREB (Figure 5A-B), or p-JNK (Figure 6A-B). We did observe a trend in JNK 
activation (p = 0.08, Figure 6A-B) over time; however, there was large variation among 
replicates. To verify any activation of MAPK signaling was induced by Buserelin, additional 
C2C12 myocytes were treated with Antide, a GnRH antagonist that binds but does not activate 
GnRHr, 30 min before Buserelin treatment. Because Antide binds the GnRHr, it inhibits 
Buserelin from binding. Treatment with Buserelin caused a significant activation of CREB at 60 
min (p = 0.0002, Figure 5C). Intriguingly, there was no effect of Buserelin on CREB activation 
when cells were pretreated with Antide (p = 0.71, Figure 5D). Further, JNK activation was lower 
across time in cultures treated with Antide prior to treatment with Buserelin compared to 
Buserelin alone; however, this was not statistically significant. 
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Figure 3: Western Blot Analysis of ERK in Myocytes. (A) Total ERK1 and (B) p-ERK protein 
levels were measured by Western blot analysis of proteins obtained from human primary 
myocytes at 6 time points after treatment with Buserelin (n = 3). (C) The ratio of p-ERK/ERK1 
protein expression was calculated to assess active ERK1 signaling. (D) Western blots of p-ERK, 
total ERK1, and ⍺-tubulin at 6 time points using protein from 3 young male donors. All blots 
were normalized to ⍺-tubulin. Data are presented as individual donors. 
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Figure 4. Western Blot Analysis of ERK in C2C12 Myocytes. (A) Δ p-ERK/ERK protein 
value (A.U.) with Antide + Buserelin or Buserelin treatment (B) p-ERK/ERK Western blot 
analysis. (C) Δ p-ERK/ERK protein value (A.U.) without Buserelin treatment (Time 0 min) and 
with Buserelin treatment (Time 60 min). (D) Δ p-ERK/ERK protein value (A.U.) 30 min after 
Antide treatment (Time 0 min) and 60 min after Buserelin treatment with Antide administration 
30 min prior to Buserelin (Time 60 min). Protein levels were measured by Western blot analysis 
of proteins obtained from C2C12 cells at 6 time points following treatment with Antide + 
Buserelin (n = 3) or Buserelin (n = 3). All blots were normalized to ⍺-tubulin and further 
normalized to Time 0 of the Buserelin treatment. A two-way ANOVA (treatment-by-time) and t 
tests comparing Time 0 min and Time 60 min were performed. All values are reported as mean ± 
s.d. Significance was determined at p < 0.05. Effect of treatment p = 0.15. Effect of Buserelin at 
60 min p = 0.17. Effect of Antide + Buserelin at 60 min p = 0.67. 
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Figure 5. Western Blot Analysis of CREB in C2C12 Myocytes. (A) Δ p-CREB/CREB protein 
value (A.U.) with Antide + Buserelin or Buserelin treatment (B) p-CREB/CREB Western blot 
analysis. (C) Δ p-CREB/CREB protein value (A.U.) without Buserelin treatment (Time 0 min) 
and with Buserelin treatment (Time 60 min). (D) Δ p-CREB/CREB protein value (A.U.) 30 min 
after Antide treatment (Time 0 min) and 60 min after Buserelin treatment with Antide 
administration 30 min prior to Buserelin (Time 60 min). All blots were normalized to ⍺-tubulin 
and further normalized to Time 0 of the Buserelin treatment. A two-way ANOVA (treatment-by-
time) and t tests comparing Time 0 min and Time 60 min were performed. All values are 
reported as mean ± s.d. Significance was determined at p < 0.05. Effect of treatment p = 0.37. 
Effect of Buserelin at 60 min p = 0.0002. Effect of Antide + Buserelin at 60 min p = 0.71. 
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Figure 6. Western Blot Analysis of JNK in C2C12 Myocytes. (A) Δ p-JNK/JNK protein value 
(A.U.) with Antide + Buserelin or Buserelin treatment (B) p-JNK/JNK Western blot analysis. 
(C) Δ p-JNK/JNK protein value (A.U.) without Buserelin treatment (Time 0 min) and with 
Buserelin treatment (Time 60 min). (D) Δ p-JNK/JNK protein value (A.U.) 30 min after Antide 
treatment (Time 0 min) and 60 min after Buserelin treatment with Antide administration 30 min 
prior to Buserelin (Time 60 min). All blots were normalized to ⍺-tubulin and further normalized 
to Time 0 of the Buserelin treatment. A two-way ANOVA (treatment-by-time) and t tests 
comparing Time 0 min and Time 60 min were performed. All values are reported as mean ± s.d. 
Significance was determined at p < 0.05. Effect of treatment p = 0.08. Effect of Buserelin at 60 
min p = 0.40. Effect of Antide + Buserelin at 60 min p = 0.48. 
 
 
 
KISS/GnRH gene expression in GEO Datasets 
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To determine whether KISS/GnRH gene expression is downregulated in the skeletal 
muscle of patients with diagnosed myopathies, we conducted secondary analyses of NCBI GEO 
datasets. We determined that the gene expression of KISS1, KISS1r, GnRH, and GnRHr was 
significantly reduced in myopathies including juvenile dermomyositis, Duchenne muscular 
dystrophy, amyotrophic lateral sclerosis, facioscapulohumeral dystrophy, tibial muscular 
dystrophy, and myotonic dystrophy type 2. KISS1 was downregulated in the skeletal muscle of 
untreated girls with juvenile dermomyositis vs. healthy controls (Figure 7) (21). GnRH2 and 
GnRHr expression were reduced in Duchenne muscular dystrophy (Figure 8), amyotrophic 
lateral sclerosis (Figure 9), and facioscapulohumeral dystrophy (Figure 10) compared to control 
skeletal muscle (22, 23). KISS1 and GnRH2 gene expression were not significantly different in 
myotonic dystrophy type 2 (p > 0.05, Figure 11) vs. control skeletal muscle (24). Gene 
expression of GnRH1, but not GnRHr trended downward in tibial muscular dystrophy vs. control 
skeletal muscle (p = 0.058, Figure 12) (24). 
 
Figure 7. KISS1 Gene Expression in Juvenile Dermomyositis. KISS1 (p = 1.25e-06) gene 
expression in control (n = 4) vs. untreated (juvenile) dermomyositis (n = 19) skeletal muscle. 
 
  40 
A B  
 
Figure 8. GnRH2 and GnRHr Gene Expression in Duchenne Muscular Dystrophy (DMD). 
(A) GnRH2 (p = 2.04e-03) and (B) GnRHr (p = 0.024) gene expression in control (n = 3) vs. 
Duchenne muscular dystrophy (DMD) (n = 5) skeletal muscle. 
 
A  B   
Figure 9. GnRH2 and GnRHr Gene Expression in Amyotrophic Lateral Sclerosis (ALS). 
(A) GnRH2 (p = 1.26e-03) and (B) GnRHr (p = 0.049) gene expression in amyotrophic lateral 
sclerosis (ALS) (n = 9) vs. control (n = 3) skeletal muscle. 
 
A  B  
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Figure 10. GnRH2 and GnRHr Gene Expression in Facioscapulohumeral Dystrophy 
(FSHD). (A) GnRH2 (p = 9.40e-03) and (B) GnRHr (p = 0.02) gene expression in control (n = 
3) vs. facioscapulohumeral dystrophy (FSHD) (n = 5) skeletal muscle.  
 
A  B  
Figure 11. KISS1 and GnRH2 Gene Expression in Myotonic Dystrophy Type 2 (DM2). (A) 
KISS1 (p = 0.55) and (B) GnRH2 (p = 0.25) gene expression in control (n = 4) vs. myotonic 
dystrophy type 2 (DM2) (n = 6) skeletal muscle. 
 
A B  
Figure 12. GnRH1 and GnRHr Gene Expression in Tibial Muscular Dystrophy (TMD). (A) 
GnRH1 (p = 0.058) and (B) GnRHr (p = 0.93) gene expression in tibial muscular dystrophy 
(TMD) (n = 7) vs. control (n = 5) skeletal muscle. 
 
To determine whether KISS1 signaling is negatively regulated with inflammation in 
tissues other than skeletal muscle, we conducted secondary analyses of available GEO datasets 
that are associated with heightened inflammation. Gene expression of KISS1r was 
downregulated in whole liver tissue of mice that underwent cecum ligation and puncture to 
produce sepsis vs. control mice (Figure 13) (25). KISS1r was downregulated in breast cancer 
cells transfected with small interfering RNA (siRNA) targeting Inhibitor of nuclear factor kappa-
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B kinase subunit beta (IKKβ), a key component of the NF-κB inflammatory signaling pathway 
(Figure 14) (26). 
 
 
 
 
 
 
 
 
 
Figure 13. KISS1r Gene Expression in Sepsis. KISS1r gene expression (p = 0.03) in whole 
liver tissue of control (sham, n = 3) and septic (n = 3) mice. 
 
 
 
 
 
 
 
 
 
 
Figure 14. KISS1r Gene Expression and Inflammation in Breast Cancer Cells. KISS1r gene 
expression (p = 0.03) in breast cancer cells (control) (n = 3) vs. breast cancer cells transfected 
with siRNA targeting IKKβ (n = 3). 
 
 
 
 
 
GnRH signaling and inflammatory cytokine gene expression 
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To explore the relationship between GnRH signaling and inflammation in skeletal 
muscle, we measured IL-6 gene expression in myocytes from young female (n = 5) and young 
male (n = 5) donors cultured in DM (control), TNFα, Buserelin, or TNFα + Buserelin for 48 h. 
As expected, treatment with TNFα significantly upregulated IL-6 mRNA levels in both males 
and females, while treatment with Buserelin had no effect under basal or inflammatory 
conditions (Figure 15). 
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Figure 15. Inflammatory Cytokine mRNA Levels in Myocytes. IL-6 mRNA expression in 
myocytes from (A) young female (n = 5) and (B) young male donors (n = 5) treated with 
differentiation media control, TNFα, Buserelin, or TNFα + Buserelin given together for 48 h. IL-
6 expression values were normalized to the housekeeper gene 18S. Two-way ANOVA were 
performed (Buserelin-by-TNFα) on the delta Cp (dCP) values. Significance was set at p < 0.05. 
T = significant effect of TNFα. 
 
 
2.5 Discussion 
 
Our research is the first to identify KISS1/GnRH in the skeletal muscle and further, this 
research identifies a potential novel link between heightened inflammation and KISS1/GnRH 
signaling. In addition to its role in the hypothalamic-pituitary-gonadal axis, KISS1 has been 
linked to inflammation in various non-muscle tissues and cell types. KISS1 inhibits the TNFα-
mediated activation of the proinflammatory NF-κB pathway in breast cancer cells (14), reduces 
NF-κB binding to the promoter in fibrosarcoma cells (15), and inhibits cancer metastasis in 
several other cancers (6, 12, 27). To our knowledge, KISS1 signaling has not been previously 
identified in skeletal muscle. Interestingly, GnRH signaling emerged as a top canonical pathway 
based on DEgenes identified between our MuIS+ and MuIS- myocyte cultures as well as 
between individuals who exhibited no response or an extreme hypertrophic response to 
resistance exercise training (28, 29). Intriguingly, those who had no response to resistance 
exercise training also had heightened expression of inflammation-related genes. While GnRH 
signaling has been identified in numerous extra-pituitary tissues, GnRH in skeletal muscle is a 
novel pathway that warranted further investigation.  
GnRHr was detected at the protein level with a β-galactosidase chemiluminescent 
reporter gene detection assay in skeletal muscle of ROSA26/GRIC but not C57BL/6J mice, 
validating the presence of GnRHr in skeletal muscle. This result revealed potential sex 
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differences, as male ROSA26/GRIC mice appeared to have increased levels of GnRHr compared 
to ROSA26/GRIC females. A recent study showed that an inflammation-induced reduction in 
spine density, a measure of excitatory synaptic input, of GnRH neurons in the hypothalamus 
occurs in male but not female mice (18). Further, administration of LPS suppressed gonadotropic 
function in male rats, likely due to a reduction in absolute responsiveness of GnRH neurons to 
KISS1 (19). Aside from inflammation, in the reproductive system, GnRH-induced ERK 
activation is required for female, but not male, fertility (8). Considering the well-recognized 
sexual dimorphism of KISS1 and GnRH signaling in other systems and evidence suggesting sex 
differences in response to inflammation, it is feasible the relationship between KISS1 and/or 
GnRH signaling and inflammation may involve sex differences in skeletal muscle. 
GnRH/GnRHr signaling through CREB may be functional in skeletal muscle; we found 
that the addition of Antide, a competitive inhibitor that binds GnRHr, diminished CREB 
activation at 60 min compared to Buserelin alone. Similar results were also observed with JNK 
and ERK activation, however the variation across replicates did not allow for statistical 
significance. The inconsistent and insufficient MAPK signaling we observed with Buserelin 
treatment could be due to the rapid and transient nature of these proteins. It is possible that 
activation occurred but was overlooked using only the specified time points. For example, Caunt 
et al. (2012) found a maximum response of GnRH-induced ERK1/2 signaling at 5 min followed 
by rapid reduction close to basal levels at 60 min in a GnRHr overexpression model of HeLa 
cells (30). In addition to inflammatory cytokines, the MAPK pathways are stimulated by growth 
factors, mitogens, and environmental stressors. (31). In skeletal muscle, MAPKs are activated by 
IGF-1, fibroblast growth factor (FGF), and numerous other signals (32, 33, 34). Due to the 
complex nature of MAPK signaling in skeletal muscle cells, the Western blot analysis method 
may be limited in its ability to detect MAPK signaling. Because Antide blunted activation by 
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Buserelin, we are fairly confident that GnRHr signaling in the muscle acts via CREB and JNK, 
however follow-up studies to confirm this signaling are necessary.  
Results from searching NCBI GEO datasets further support the notion that there is a 
relationship between KISS1/GnRH and inflammation in the skeletal muscle; KISS1/GnRH 
signaling may be downregulated in various myopathies. However, this theory was not supported 
in myocyte culture when we treated myocytes with TNFa + Buserelin for 48 h. Buserelin had no 
significant effect on TNFa-mediated IL-6 expression in myocytes from males or females. 
Similar to the human myocyte and C2C12 myocyte experiments using Western blot analysis to 
determine GnRH-induced MAPK signaling in skeletal muscle, these results may have excluded 
the transient length of time that Buserelin alters TNFa-mediated IL-6 expression. It is also 
possible that the directionality of the relationship may be contrary to the original hypothesis; 
KISS1/GnRH signaling in skeletal muscle may be diminished in response to inflammation. 
However, this theory is challenging to test due to the insufficiency of high-quality antibodies for 
KISS1, GnRH, and GnRHr. 
Other hormones central to the mammalian reproductive system have been shown to also 
regulate skeletal muscle homeostasis and regeneration under basal and inflammatory conditions. 
Oxytocin, best known for its role in lactation, parturition and behavior, is required for skeletal 
muscle homeostasis and successful regeneration (35). Plasma levels of oxytocin decline with age 
and a genetic disruption of oxytocin is associated with premature muscle atrophy and impaired 
muscle function. Estrogen, the primary mammalian female sex hormone, is also known to 
stimulate muscle repair and regeneration, including satellite cell activation and proliferation. In 
female mice, prolonged estrogen deficiency leads to a shift towards glycolytic myofiber types, 
impaired SC function, diminished regenerative capacity, and muscle atrophy (36). Estrogen 
alleviates the loss of skeletal muscle mass associated with sepsis and blunts sepsis-induced 
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hypothalamic inflammation and dysregulation of hypothalamic neuropeptides (37). Estrogen 
lowered training-induced muscle damage in post-menopausal women (38). Intriguingly, our 
previous research showed that β-estradiol, the predominant estrogen hormone, was predicted to 
be activated as an upstream regulator in MuIS-, suggesting that β-estradiol was elevated in the 
skeletal muscle of MuIS- individuals prior to the observed increase in KISS1 gene expression. In 
the hypothalamus, estrogen exerts both positive and negative feedback regulation on GnRH 
release through KISS1 neurons (39). It is possible that estrogen regulates KISS1 expression in 
skeletal muscle. 
 
Limitations 
KISS1 signals through GnRH, however, KISS1 protein or gene expression was not 
examined in this study due to time constraints and limitations of commercial antibodies currently 
available. It is possible that the association between KISS1 and inflammation in skeletal muscle 
is independent of GnRH. There are other potential pathways by which KISS1 and/or GnRH 
signals to regulate inflammation in skeletal muscle. 
 
2.6 Conclusion 
These results confirm that GnRHr protein is present and functional in skeletal muscle. 
Further, these results demonstrate that KISS1/GnRH have a relationship with inflammation that 
is impacted with inflammatory susceptibility and myopathies. Future research should focus on 
identifying phenotypes associated with a lack of KISS1 or GnRH signaling in skeletal muscle; 
KISS1/GnRH is a potential therapeutic target to attenuate heightened inflammation in disease 
states.  
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CHAPTER 3. DISCUSSION 
 
3.1 Summary of the relationship between KISS1/GnRH signaling and inflammation in 
skeletal muscle 
Chronic muscle inflammation contributes to skeletal muscle atrophy and impaired 
regenerative capacity (1, 2). Skeletal muscle inflammatory susceptibility, or the ability to 
manage and respond to inflammation, has been identified as a predictor of failed skeletal muscle 
regeneration and regrowth following surgery (3, 4). This inflammatory susceptibility is 
associated with human aging and likely contributes to the adverse structural, metabolic, and 
functional tissue remodeling that occurs in aged adults (3). As the etiology for heightened 
inflammation in skeletal muscle is unclear, particularly in healthy young adults, research that 
elucidates the mechanisms by which inflammation impairs skeletal muscle regeneration is 
necessary for identifying potential therapeutic targets. 
Previous research from our laboratory identified that kisspeptin-1 (KISS1) was the most 
highly differentially expressed gene (DEgene) between cells from donors with (MuIS+) and 
without (MuIS-) inflammatory susceptibility (downregulated 21.4-fold [MuIS+/MuIS-]) and was 
a node in the top network of DEgenes following pathway analysis (5). In addition to stimulating 
the release of gonadotropin-releasing hormone (GnRH) in the hypothalamus, KISS1 has been 
linked to inflammation in various cell types (6). KISS1 inhibits the tumor necrosis factor alpha 
(TNFa)-mediated activation of the proinflammatory nuclear factor kappa-light-chain-enhancer 
of activated B cells (NF-κB) pathway in breast cancer cells (7), reduces NF-κB binding to the 
promoter in fibrosarcoma cells (8), and inhibits cancer metastasis in multiple other cancers (6, 9, 
10, 11, 12). Interestingly, GnRH signaling emerged as a top canonical pathway common in both 
the MuIS- myocytes and in individuals who exhibited hypertrophic responses to resistance 
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exercise training (13, 14). In the present study, we aimed to investigate the potential relationship 
between KISS1/GnRH signaling and inflammation in skeletal muscle.  
We confirmed the presence of the GnRH receptor (GnRHr) in skeletal muscle with a 
gene detection assay using skeletal muscle obtained from ROSA26/GRIC mice. This assay also 
revealed potential sex differences that require further exploration. We used differentiated human 
primary muscle stem cells (i.e., myocytes) and differentiated immortalized murine myoblast cells 
(C2C12 myocytes) treated with Buserelin, a GnRH analog, to investigate canonical downstream 
GnRH/GnRHr signaling through the mitogen-activated protein kinase (MAPK) pathways: 
extracellular-regulated kinase (ERK), Jun N-terminal kinase (JNK), and the downstream 
transcription factor cAMP response element-binding protein (CREB). The MAPK signaling 
pathways regulate cellular processes including cell proliferation, differentiation, and survival or 
apoptosis (15, 16). The addition of Antide, a competitive inhibitor that binds GnRHr, diminished 
CREB activation at 60 min compared to Buserelin alone, suggesting GnRH/GnRHr signaling, 
through CREB, may be functional in skeletal muscle. Results from searching NCBI GEO 
datasets revealed that KISS1/GnRH signaling may be downregulated in various inflammatory 
myopathies. However, this concept was not supported in myocyte culture when we treated 
myocytes with Buserelin and TNFα, a pro-inflammatory cytokine, prior to measuring 
inflammatory cytokine mRNA levels. 
Our methods may have been insufficient to detect the transient length of time that 
Buserelin would activate MAPK pathways or influence the TNFα-mediated increase in IL-6 
mRNA levels. Due to time constraints and limitations of commercial antibodies currently 
available, KISS1, GnRH, or GnRHr protein levels could not be examined in this study. It is 
possible that the association between KISS1 and inflammation in skeletal muscle is independent 
of GnRH. 
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3.2 Unexplored pathways potentially associated with KISS1/GnRH in skeletal muscle 
There are additional mechanisms by which KISS1 and/or GnRH may regulate 
inflammation in skeletal muscle that were not explored in the present study. For example, matrix 
metalloproteases (MMPs) are a class of enzymes involved in the regulation of extracellular 
matrix degradation in many tissues, and regulate cell migration, differentiation, and regeneration 
in skeletal muscle (17). The activity of MMP-9, expressed in polymorphonuclear leukocytes and 
macrophages, is upregulated for the first three days following skeletal muscle injury and aids in 
satellite cell activation. Bani et al. (2008) found that inflammation and necrosis of the skeletal 
muscle tissue was associated with an increase in the activity of MMP-9 and TNFa, and that 
increased MMP‐2 activity may reflect the extent of disease progression in dystrophic muscle 
(18). Both MMP-2 and MMP-9 participate in post-translational modification of KISS1. KISS1 
binding to KISS1r has been shown to dephosphorylate NF-κB in fibrosarcoma cells, resulting in 
dissociation from the MMP-9 promoter via a MAPK-independent mechanism (8). In addition, 
MMP-9 expression was reduced in colorectal cancer cells with the addition of KISS1 and an 
ERK1/2 inhibitor (10). It is plausible KISS1 exerts a regulatory effect on NF-κB through MMP-9 
in skeletal muscle, independent of MAPK signaling.  
Calcium signaling emerged as the most significant and highly activated canonical 
pathway in MuIS- myocytes compared to MuIS+ myocytes and several components of the 
calcium signaling pathway were upregulated in MuIS- cells. Additionally, two top pathways 
shared by MuIS- and extreme responders to resistance training included GnRH signaling and 
calcium signaling. Calcium, which exerts allosteric effects on a wide array of intracellular 
proteins and functions as a signal transducer in most body tissues, is necessary for myogenesis. 
Satellite cell recruitment, activation, and proliferation triggered by mechanical stimuli is ablated 
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with inhibition of L-type calcium channels (19). Transcription factors, including CREB and other 
MAPK-stimulated factors, transmit the calcium signal in skeletal muscle. Stimulus-driven 
calcium-dependent phosphorylation of ERK and CREB leads to an upregulation of the genes c-
FOS, c-JUN, and EGR1. Calcium release mediated by type 1 inositol 1,4,5-trisphosphate 
receptors is essential for human myoblast differentiation, but not for muscle regeneration (19). 
The mechanisms regulating calcium signaling during satellite cell activation and muscle 
regeneration have yet to be fully elucidated. Dysregulated calcium signaling has also been linked 
to cachexia and other inflammation-centered myopathies such as myositis (20). 
In the pituitary gonadotrope, GnRH is a calcium signaling modulator. GnRH action 
requires calcium to activate ERK, which subsequently facilitates L-type calcium influx (21, 22). 
GnRH-mediated intracellular mobilization of calcium activates calcium-calmodulin-dependent 
protein kinases (CaMK) and the calcium-calmodulin-dependent phosphatase calcineurin. The 
expression of calcineurin is required for skeletal muscle differentiation and is upregulated along 
with voltage-gated calcium channels in MuIS-/MuIS+ myocytes (23). In systems such as the 
pituitary and clonal gonadotrope cells, GnRHr couples to G⍺s and stimulates cAMP. Activation 
of calcium/calmodulin-sensitive adenylyl cyclase isoforms independent of Gαs has been 
proposed as the mechanism of GnRHr-induced cAMP elevation (21, 24, 25). It is possible that 
GnRH acts in a calcium-dependent manner to activate ERK and regulate proinflammatory 
pathways in skeletal muscle. 
Actin cytoskeleton development is a critical process in skeletal muscle regeneration, 
essential for normal cell division during differentiation, myoblast fusion, muscle elongation and 
attachment, muscle maturation, and sarcomere assembly (26). GnRH signaling and actin 
cytoskeleton signaling emerged as top canonical pathways shared by MuIS- myocytes and 
extreme responders to resistance training. GnRH signaling has been shown to directly induce 
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actin cytoskeleton remodeling and cell migration in prostate cancer cell lines (27). There is also 
evidence that KISS1 itself acts downstream of cell-matrix adhesion involving cytoskeletal 
reorganization, as well as in positive regulation of cytosolic calcium ion concentration (9, 28). 
Cytoskeleton remodeling has been proposed as a mechanism of KISS1/KISS1r anti-metastatic 
action in breast cancer cells (9). We have shown for the first time that KISS1/KISS1r signaling is 
downregulated in several myopathies, and the majority of skeletal muscle myopathies are 
directly linked to a lack of function in cytoskeletal components (26). It is plausible that KISS1 
and/or GnRH contribute to myogenesis via actin cytoskeleton development and remodeling. 
 The p38 MAPK pathway is also a potential mediator of KISS1/GnRH signaling in 
skeletal muscle. p38 regulates myogenesis during satellite cell activation and asymmetric 
division, proliferation, and differentiation (18, 29, 30). Bernet et al. (2014) showed that p38 plays 
a crucial role in self-renewal of satellite cells; satellite cells from aged mice fail to regain self-
renewal capacity following transplantation into a young microenvironment, likely due to 
dysregulated p38 MAPK signaling (31). It is possible that KISS1 and/or GnRH acts through p38 
MAPK to maintain homeostatic MAPK signaling during inflammation in skeletal muscle. 
In addition to KISS1, the transcription factor early growth response 1 (EGR1) was 
identified as another top node in MuIS- compared to MuIS+ myocytes. EGR1 regulates cell 
differentiation, growth, inhibition of growth, and apoptosis (32, 33). KISS1 induces transcription 
of EGR1 in gonadotropes in vitro (34) and EGR1 has antiproliferative effects in pancreatic 
cancer cells alongside the anti-metastasis effects of KISS1 (35). Zhang et al. (2017) found that 
EGR1 promotes differentiation of bovine skeletal muscle-derived satellite cells by upregulating 
gene expression of Myogenin, a transcription factor required for myogenesis (36). In the early 
inflammatory stage of the skeletal muscle repair process, EGR1 is activated by IL-1β and is 
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associated with IL-6 following crush injury in vivo (37, 38, 39). EGR1 is a potential transcription 
factor that KISS1 could act through to regulate inflammatory signaling during myogenesis. 
Apart from KISS1, several hormones central to the mammalian reproductive system have 
been shown to also regulate skeletal muscle homeostasis and regeneration under basal and 
inflammatory conditions. Oxytocin, best known for its role in lactation, parturition and behavior, 
is required for skeletal muscle homeostasis and successful regeneration (40). A genetic knock-
out of oxytocin in mice resulted in premature muscle atrophy and impaired muscle function (40). 
Estrogen, the primary female sex hormone, is also known to stimulate muscle repair and 
regeneration, including SC activation and proliferation. Prolonged estrogen deficiency in female 
mice leads to a shift towards glycolytic myofiber types, impaired SC function, diminished 
regenerative capacity, and muscle atrophy (41). Estrogen alleviates the loss of skeletal muscle 
mass associated with sepsis and blunts sepsis-induced hypothalamic inflammation and 
dysregulation of hypothalamic neuropeptides (42). In post-menopausal women, estrogen lowered 
training-induced muscle damage (43). Our previous research showed that β-estradiol signaling 
was predicted to be activated as an upstream regulator in MuIS-, suggesting that β-estradiol is 
elevated in the skeletal muscle of MuIS- individuals prior to the observed increase in KISS1 
gene expression. In the hypothalamus, estrogen exerts both positive and negative feedback 
regulation on GnRH release through KISS1 neurons (44). It is feasible that estrogen regulates 
KISS1 expression in skeletal muscle. 
 
3.3 Future directions 
Although our research suggests a potential link between KISS1/GnRH signaling and 
inflammatory myopathies, we did not identify the role(s) of these hormones in skeletal muscle. 
Future research should focus on identifying phenotypes associated with a lack of KISS1 in 
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skeletal muscle. A KISS1 knockdown in vitro model using small interfering RNA (siRNA) or 
short hairpin RNA (shRNA) or a muscle-specific KISS1 knockout in vivo model could 
contribute to this line of questioning. Due to the lack of sufficient commercial antibodies 
targeting KISS1, KISS1r, GnRH, and GnRHr, the levels of these proteins could be determined in 
cell lysate from an in vitro model or tissue homogenate from an in vivo model using liquid 
chromatography–mass spectrometry (LC-MS). To determine the nature of the relationship 
between KISS1 or GnRH signaling and inflammation in skeletal muscle, the expression of 
proinflammatory genes in the tissue homogenate from an in vivo KISS1 knockout model could 
be assessed using RNA sequencing. In further experiments to determine mechanistic pathway by 
which KISS1/GnRH signals in skeletal muscle, ELISA would be a useful method to measure 
transient ERK phosphorylation. 
As the results of searching the NCBI GEO datasets revealed that KISS1 and/or GnRH 
may be associated with myopathies including Duchenne muscular dystrophy, juvenile 
dermomyositis, tibial muscular dystrophy, facioscapulohumeral dystrophy, myotonic dystrophy 
type 2, and amyotrophic lateral sclerosis, future research should investigate the effects of a 
KISS1 knockout or overexpression in vivo model of an inflammatory myopathy. Our results 
suggest a striking downregulation of KISS1 in skeletal muscle from individuals with JDM 
compared to healthy controls. A transgenic mouse model of myositis, such as the model 
developed by Li et al. (2009), may be the most appropriate model to study downstream effects of 
genetic disruption of KISS1 (45). 
In conclusion, our results confirmed that GnRHr protein is present and functional in 
skeletal muscle and that KISS1/GnRH have a relationship with inflammation that is impacted 
with muscle inflammatory susceptibility and myopathies. In addition to MAPK signaling, 
KISS1/GnRH may impact inflammation in skeletal muscle through the regulation of MMP-9, 
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calcium signaling, actin cytoskeleton remodeling, p38 MAPK, and/or EGR1. It is possible that 
estrogen regulates KISS1 expression in skeletal muscle. Future research should focus on 
identifying phenotypes associated with a genetic lack of KISS1 signaling in skeletal muscle and 
investigate the role of KISS1 in an in vivo model of inflammatory myopathy.  
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